Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZIHKY)

Drug Name

XMD8-92 Drug Info

Synonyms

XMD 8-92

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Patented Agent(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Extracellular signal-regulated kinase 5 (ERK5)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID26924192-Compound-30	DMWXNIJ	N. A.	N. A.	Patented	[2]
PMID26924192-Compound-32	DM0JSOZ	N. A.	N. A.	Patented	[2]
PMID26924192-Compound-33	DM9NWXM	N. A.	N. A.	Patented	[2]
------------------------------------------------------------------------------------

Drug(s) Targeting Polo-like kinase 4 (PLK4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CFI-400945	DM3BN4W	Breast cancer	2C60-2C65	Phase 2	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Doublecortin-like kinase 2 (DCLK2)	TTHK3MO	DCLK2_HUMAN	Inhibitor	[1]
Extracellular signal-regulated kinase 5 (ERK5)	TTU6FSC	MK07_HUMAN	Inhibitor	[1]
Non-receptor tyrosine-protein kinase TNK1 (TNK1)	TTWS7I3	TNK1_HUMAN	Inhibitor	[1]
Polo-like kinase 4 (PLK4)	TTGPNZQ	PLK4_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein. Cancer Cell. 2010 Sep 14;18(3):258-67.
2	BET inhibitors in cancer therapeutics: a patent review.Expert Opin Ther Pat. 2016;26(4):505-22.
3	Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014 Aug 11;26(2):163-76.